

Claims

1. The use of hyaluronic acid for the production of a composition for preventing or treating inflammatory skin or mucous membrane diseases.

2. The use as claimed in claim 1,
characterized in that
a composition for local administration is produced.

3. The use as claimed in claim 1 or 2,
characterized in that
a composition for intradermal administration, for administration to the border of the dermoepithelial transition or for topical administration is produced.

4. The use as claimed in one of claims 1 to 3,
characterized in that
the hyaluronic acid is present in uncrosslinked form.

5. The use as claimed in claim 4,
characterized in that
the hyaluronic acid is selected from
(i) long-chain hyaluronic acid having an average molecular weight (weight-average) of at least 200 kD and
(ii) short-chain hyaluronic acid having an average molecular weight (weight-average) up to 50 kD or mixtures thereof.

6. The use as claimed in one of claims 1 to 3,
characterized in that
the hyaluronic acid is present in crosslinked form.

7. The use as claimed in claim 6,
characterized in that
the degree of crosslinking is in the range from 0.1% to 10%.

8. The use as claimed in one of claims 1 to 7,
characterized in that
the hyaluronic acid is present as a mixture of
uncrosslinked and crosslinked hyaluronic acid.

9. The use as claimed in one of claims 1 to 8,
characterized in that
the composition furthermore contains an inhibitor of
hyaluronic acid degradation.

10. The use as claimed in claim 6,
characterized in that
the inhibitor of hyaluronic acid degradation is
selected from heparin, indomethacin, salicylates, free
radical traps, such as vitamin A, C or E, and mixtures
thereof.

11. The use as claimed in one of claims 1 to 10,
characterized in that
the hyaluronic acid is present as an injectable
preparation, ointment, cream, lotion, gel, spray,
tincture, shampoo, occlusive film, powder or inhalable
preparation.

12. The use as claimed in one of claims 1 to 11,
characterized in that
the composition furthermore contains another glycos-
aminoglycan in crosslinked or uncrosslinked form.

13. The use as claimed in one of claims 1 to 12,
characterized in that
the inflammatory skin or mucous membrane disease is
selected from atopic dermatitis, eczemas, such as
seborrheic and microbial eczemas, pruritus, prurigo,
urticaria, red lichen, psoriasis, such as psoriasis
vulgaris, vitiligo, viral skin diseases which lead to
wart formation, such as verruca vulgaris or Condylomata
acuminata, rosacea, perioral dermatitis, acne, such as

acne vulgaris or acne conglobata, polypous mucous membrane diseases, such as nasal polyposis, and inflammatory intestinal diseases, chronic or acute ulcerations of the skin, aphthae and mycoses.

14. The use as claimed in one of claims 1 to 13 in human medicine.

15. The use as claimed in one of claims 1 to 13 in veterinary medicine.

16. A process for preventing or treating an inflammatory skin or mucous membrane disease, **characterized in that** a preparation is administered to a subject to be treated, which contains hyaluronic acid in an amount adequate for treating the disease.

17. The use of crosslinked hyaluronic acid for the production of a composition for preventing or treating inflammatory diseases of the eye.

18. The use as claimed in claim 17 for preventing or treating inflammatory diseases of the conjunctiva or cornea.

19. The use as claimed in claim 17 or 18 for preventing or treating after-cataract or inflammation of the conjunctiva.

20. The use as claimed in one of claims 17 to 19, **characterized in that** the hyaluronic acid is present as a mixture of uncrosslinked and crosslinked hyaluronic acid.

21. The use as claimed in one of claims 17 to 20, **characterized in that** the composition furthermore contains another glycosaminoglycan in crosslinked or uncrosslinked form.

22. The use of a mixture of crosslinked and non-crosslinked hyaluronic acid for the production of a cosmetic or pharmaceutical composition for treating skin or soft tissue defects and skin wrinkles.

23. The use as claimed in claim 22,
characterized in that
the composition furthermore contains another glycosaminoglycan in crosslinked or uncrosslinked form.